RBCC Joint Venture's Technology Could Lead to Cancer-Fighting Breakthrough
NOKOMIS, Fla.--(BUSINESS WIRE)-- Advanced cell-culturing technology developed by Nano3D BioSciences (n3D), the joint venture partner of Rainbow Coral Corp.'s (OTCBB: RBCC) biotech subsidiary Rainbow Biosciences, will soon be put to use reducing cancer risks caused by obesity.
Following the publication of a study co-authored by n3D's Dr. Glauco Souza demonstrating the effectiveness of the n3D Bio-Assembler in culturing three-dimensional tissues from stem cells, the device will immediately be put to use in cutting-edge cancer research.
Dr. Mikhail Kolonin, an associate professor at the University of Texas Health Science Center at Houston, is the author of a new study detailing how cancerous tumors actually "feed" on fat cells. His research, published in the journal Cancer Research and it is entitled "Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment," proves that actual stem cells from fat were migrating through the bloodstream in mice and lodging in tumors, helping them to grow and build blood vessels.
In essence, the tumors were fattening up at the cellular level.
For the next phase of this research, n3D's Bio-Assembler will be crucial. The direction of this work is to use human cells paired with magnetically levitated three-dimensional cell culturing. This research will shed new light on the relationship between cancer and obesity in a human tissue microenvironment, potentially leading to new drugs capable of "starving" tumors and dramatically reducing cancer risks from obesity.
"This will be exactly the sort of high-profile research that the n3D Bio-Assembler was designed to facilitate," said RBCC CEO Patrick Brown. "When the results of this new study are published in respected medical journals, researchers around the world are going to want to harness the power of the Bio-Assembler to advance their own work."
The Bio-Assembler's fusion of magnetic levitation and nanoparticle assembly technologies allow it to produce accurate, 3D representations of in vivo tissues faster and easier than any competing tools. The groundbreaking device is key to RBCC's plans to participate in the impressive upside in store for n3D.
RBCC's relationship with n3D is only one of the partnerships putting the company on the cutting edge of biotech innovation. Last week, RBCC finalized a new joint venture with Amarantus BioSciences (OTCBB: AMBS), the makers of a game-changing diagnostic blood test for Parkinson's disease.
Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (NAS: AMGN) , Cell Therapeutics, Inc. (NAS: CTIC) and Abbott Laboratories (NYS: ABT) .
For more information on Rainbow BioSciences, please visit www.rainbowbiosciences.com/investors.
Follow us on Twitter at www.twitter.com/RBCCinfo.
About Rainbow BioSciences
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at www.rainbowbiosciences.com. For investment information and performance data on the company, please visit www.RainbowBioSciences.com/investors.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
KEYWORDS: United States North America Florida
The article RBCC Joint Venture's Technology Could Lead to Cancer-Fighting Breakthrough originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.